Investors focused on the Medical space have likely heard of Biogen (BIIB - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Biogen is a member of our Medical group, which includes 760 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. BIIB is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BIIB's full-year earnings has moved 6.25% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, BIIB has moved about 4.05% on a year-to-date basis. At the same time, Medical stocks have gained an average of 3.06%. As we can see, Biogen is performing better than its sector in the calendar year.
Looking more specifically, BIIB belongs to the Medical - Biomedical and Genetics industry, which includes 280 individual stocks and currently sits at #106 in the Zacks Industry Rank. This group has lost an average of 2.64% so far this year, so BIIB is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to BIIB as it looks to continue its solid performance.